Trial Flaw Hold-Up With Osiris' Prochymal In Crohn's Not A Factor In GvHD

Osiris Therapeutics’ decision to stop enrolling Phase III trials with Prochymal in Crohn’s disease does not go far toward predicting outcomes in its lead indication of graft vs. host disease, given the difference between methods of efficacy measurements between the two conditions.